A number of other research firms have also recently issued reports on VYGR. BidaskClub raised shares of Voyager Therapeutics from a hold rating to a buy rating in a research note on Saturday, February 24th. BTIG Research reissued a buy rating and issued a $32.00 price target on shares of Voyager Therapeutics in a research note on Sunday, March 11th. Piper Jaffray reissued a buy rating and issued a $40.00 price target on shares of Voyager Therapeutics in a research note on Monday, March 12th. Wedbush cut shares of Voyager Therapeutics from an outperform rating to a neutral rating and set a $29.00 price target on the stock. in a research note on Monday, March 12th. Finally, Morgan Stanley lifted their price target on shares of Voyager Therapeutics from $36.00 to $39.00 and gave the company an overweight rating in a research note on Wednesday, February 21st. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $29.73.
Voyager Therapeutics stock opened at $19.66 on Monday. Voyager Therapeutics has a 1 year low of $8.10 and a 1 year high of $31.91. The firm has a market capitalization of $619.34, a P/E ratio of -7.45 and a beta of 2.97.
In other Voyager Therapeutics news, insider Bernard Ravina sold 2,451 shares of Voyager Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $18.24, for a total transaction of $44,706.24. Following the sale, the insider now owns 4,902 shares of the company’s stock, valued at approximately $89,412.48. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Dinah Ph.D. Sah sold 15,623 shares of Voyager Therapeutics stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total transaction of $468,690.00. Following the sale, the insider now directly owns 140,872 shares in the company, valued at approximately $4,226,160. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 66,908 shares of company stock worth $1,574,258. 8.00% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Thompson Davis & CO. Inc. boosted its stake in Voyager Therapeutics by 67.7% during the 4th quarter. Thompson Davis & CO. Inc. now owns 7,485 shares of the company’s stock worth $124,000 after purchasing an additional 3,021 shares during the last quarter. MetLife Investment Advisors LLC acquired a new stake in Voyager Therapeutics during the 4th quarter worth $128,000. California State Teachers Retirement System boosted its stake in Voyager Therapeutics by 8.4% during the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock worth $231,000 after purchasing an additional 2,000 shares during the last quarter. Bailard Inc. acquired a new stake in Voyager Therapeutics during the 4th quarter worth $232,000. Finally, JPMorgan Chase & Co. acquired a new stake in Voyager Therapeutics during the 3rd quarter worth $270,000. 78.22% of the stock is currently owned by institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.